Literature DB >> 17726157

Inhibition of renal dipeptidyl peptidase IV enhances peptide YY1-36-induced potentiation of angiotensin II-mediated renal vasoconstriction in spontaneously hypertensive rats.

Edwin K Jackson1, Mingdi Zhang, Weili Liu, Zaichuan Mi.   

Abstract

Dipeptidyl peptidase IV inhibitors are a new class of antidiabetic drugs. It is urgent, therefore, to fully understand the pharmacology of these inhibitors. Although dipeptidyl peptidase IV metabolizes at least 24 endogenous substrates, the pharmacological consequences of inhibiting the metabolism of most of these substrates is unknown. Our previous results show that Y(1) receptors, but not Y(2) receptors, enhance renovascular responses to angiotensin II in kidneys from genetically susceptible animals (spontaneously hypertensive rats). Dipeptidyl peptidase IV converts peptide YY(1-36) (circulating hormone) to peptide YY(3-36), and peptide YY(1-36) is a Y(1)-receptor agonist, whereas peptide YY(3-36) is a selective Y(2)-receptor agonist. Therefore, it is conceivable that inhibition of dipeptidyl peptidase IV in genetically susceptible kidneys may increase the ability of peptide YY(1-36) to potentiate angiotensin II-induced renal vasoconstriction. Here we demonstrate that in kidneys from spontaneously hypertensive rats 1) peptide YY(1-36) potentiates renovascular responses to angiotensin II, whereas peptide YY(3-36) has little effect, 2) 3-N-[(2S,3S)-2-amino-3-methylpentanoyl]-1,3-thiazolidine (P32/98) (dipeptidyl peptidase IV inhibitor) augments the ability of peptide YY(1-36) to enhance renovascular responses to angiotensin II, 3) dipeptidyl peptidase IV is expressed in preglomerular microvessels and glomeruli, 4) kidneys metabolize arterial PYY(1-36) to PYY(3-36) via a mechanism blocked by P32/98, and 5) preglomerular microvessels and glomeruli convert peptide YY(1-36) to peptide YY(3-36), and this conversion is inhibited by P32/98. We conclude that dipeptidyl peptidase IV is expressed in the renal microcirculation and inhibition of this ecto-enzyme causes arterial PYY(1-36) to more effectively enhance angiotensin II-induced renal vasoconstriction in genetically susceptible kidneys.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17726157     DOI: 10.1124/jpet.107.126847

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.

Authors:  Edwin K Jackson; Zaichuan Mi; Stevan P Tofovic; Delbert G Gillespie
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

2.  Effects of liraglutide, a glucagon-like peptide-1 analog, on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.

Authors:  Tsuyoshi Nozue; Masayo Yamada; Tetsuji Tsunoda; Hiromasa Katoh; Shimpei Ito; Taku Iwaki; Ichiro Michishita
Journal:  Heart Vessels       Date:  2015-08-21       Impact factor: 2.037

3.  Endogenous adenosine contributes to renal sympathetic neurotransmission via postjunctional A1 receptor-mediated coincident signaling.

Authors:  Edwin K Jackson; Dongmei Cheng; Stevan P Tofovic; Zaichuan Mi
Journal:  Am J Physiol Renal Physiol       Date:  2011-11-23

4.  NPY1-36 and PYY1-36 activate cardiac fibroblasts: an effect enhanced by genetic hypertension and inhibition of dipeptidyl peptidase 4.

Authors:  Xiao Zhu; Delbert G Gillespie; Edwin K Jackson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-14       Impact factor: 4.733

5.  Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome.

Authors:  David S Tofovic; Victor P Bilan; Edwin K Jackson
Journal:  Clin Exp Pharmacol Physiol       Date:  2010-03-30       Impact factor: 2.557

Review 6.  Cardiovascular biology of the incretin system.

Authors:  John R Ussher; Daniel J Drucker
Journal:  Endocr Rev       Date:  2012-02-08       Impact factor: 19.871

7.  Extracellular Ubiquitin(1-76) and Ubiquitin(1-74) Regulate Cardiac Fibroblast Proliferation.

Authors:  Edwin K Jackson; Eric Mi; Vladimir B Ritov; Delbert G Gillespie
Journal:  Hypertension       Date:  2018-10       Impact factor: 10.190

8.  Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension.

Authors:  Edwin K Jackson; Zaichuan Mi
Journal:  Hypertension       Date:  2008-04-28       Impact factor: 10.190

Review 9.  Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria.

Authors:  Martin Haluzík; Jan Frolík; Ivan Rychlík
Journal:  Int J Endocrinol       Date:  2013-09-05       Impact factor: 3.257

Review 10.  Dipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protection.

Authors:  Angelo Avogaro; Saula de Kreutzenberg; Gianpaolo Fadini
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.